Webinar: Financing the Cure: Exploring the Ecosystem of Alzheimer’s Disease Research Funding
The Accelerate Cures/Treatments for All Dementias (ACT-AD) held a webinar on July 13, 2021 for an in-depth…
more.Published April 26, 2021
Neuropsychiatric symptoms—or NPS—are the mood and emotional symptoms of dementias and other brain diseases that are often overlooked and undertreated. They can have an enormous negative impact on the patient, their loved ones, and their caregivers. Neuropsychiatric symptoms are often the earliest sign of Alzheimer’s disease—occurring even before a diagnosis. When combined with the early memory loss and cognitive changes, people with Alzheimer’s can find that they have trouble managing finances, miss appointments, lose interest in things they previously enjoyed, jeopardize relationships with loved ones and family members, and even get themselves into dangerous situations. This short film addresses why we need to shake the stigma and recognize neuropsychiatric symptoms as a medical condition that can be treated to lessen the burden of already devastating diseases.
The Accelerate Cures/Treatments for All Dementias (ACT-AD) held a webinar on July 13, 2021 for an in-depth…
more.On December 7, 2020, ACT-AD held a webinar on cutting-edge research on Lewy Body dementia (LBD). The webinar…
more.The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition held an educational webinar on April 18, 2019 on…
more.The Alzheimer’s Disease Policy Task Force is an ad hoc coalition of patient, family caregiver, and professional organizations, working collectively to organize and educate the Alzheimer’s disease community and decisionmakers on the Food & Drug Administration’s (FDA) Accelerated Approval pathway, and the Centers for Medicare & Medicaid Services’ (CMS) coverage determination processes for amyloid-targeted monoclonal antibody therapies for the treatment of Alzheimer’s disease.